PURE Bioscience, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.2M | $2.0M | $1.9M | $1.8M | $3.7M | $6.9M | $1.9M |
| Cost of Revenue | $992.0K | $899.0K | $811.0K | $906.0K | $853.0K | $1.9M | $2.9M | $728.0K |
| Gross Profit | $1.3M | $1.3M | $1.2M | $971.0K | $1.0M | $2.1M | $4.0M | $1.2M |
| Gross Margin | 57.3% | 59.3% | 58.9% | 51.9% | 55.2% | 56.1% | 58.1% | 61.9% |
| Operating Expenses | ||||||||
| Research & Development | $332.0K | $316.0K | $302.0K | $297.0K | $319.0K | $339.0K | $322.0K | $354.0K |
| SG&A Expense | $3.1M | $3.3M | $4.0M | $4.3M | $4.1M | $4.0M | $3.7M | $6.4M |
| Operating Income | $-2.1M | $-2.3M | $-3.2M | $-3.9M | $-3.7M | $-2.3M | $4.0K | $-5.6M |
| Operating Margin | -90.0% | -103.4% | -163.2% | -210.7% | -205.4% | -62.5% | 0.1% | -292.8% |
| Interest Expense | $396.0K | $287.0K | $143.0K | $14.0K | $6.0K | $4.0K | $5.0K | $6.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $1.7K | $1.7K | $1.7K | $1.7K |
| Net Income | $-2.5M | $-2.4M | $-3.4M | $-4.0M | $-3.5M | $-2.3M | $4.0K | $-6.6M |
| Net Margin | -107.3% | -109.1% | -171.4% | -211.7% | -192.6% | -62.7% | 0.1% | -343.3% |
| EPS (Basic) | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.03 | $0.00 | $-0.09 |
| EPS (Diluted) | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.03 | $0.00 | $-0.09 |
| Shares Outstanding (Basic) | 116.5M | 111.9M | 111.9M | 111.4M | 88.8M | 87.2M | 82.2M | 72.9M |
| Shares Outstanding (Diluted) | 116.5M | 111.9M | 111.9M | 111.4M | 88.8M | 87.2M | 84.6M | 72.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |